AccuMetab™ Human CYP2C18 Enzyme, Catalytically Active

CAT#: ITS-0426-YL27
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2C18 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Although it shares high sequence homology with other CYP2C family members, CYP2C18 exhibits significantly lower hepatic expression and restricted xenobiotic activity. It is primarily utilized in exhaustive Phase I profiling panels to confirm structural selectivity and map minor metabolic pathways.
Key Features
Minor hepatic isoform for exhaustive ADME panels; Identifies secondary clearance mechanisms; Prevents undiscovered metabolic side-reactions; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry